PCSK9 and myocardial infarction: Two antibody‐based PCSK9 inhibitors have been successfully developed for clinical use, proving effective in lowering cholesterol levels and reducing the risk of ASCVD events, including myocardial infarction, stroke, and death, without significant adverse effects [22].